Page 13 - Potential Risk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 sp...

Share this article Share this article INDIANAPOLIS, Jan. 26, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, "events") in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial, Eli Lilly and Company (NYSE: LLY) announced. Across 1,035 patients, there were 11 events (2.1 percent) in patients taking therapy and 36 events (7.0 percent) in patients taking placebo, representing a 70 percent risk reduction (p= 0...

/PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care...

Share this article Share this article INDIANAPOLIS, Dec. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico. Conducting the study in New Mexico will allow for the collection of data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. Bamlanivimab recently received Emergency Use Authorization (EUA...

There's two options. one, there's new intelligence, more specific intelligence, the administration has not been direct about that. the other is that a new administration has come in. and has looked at the previous threat stream and maybe their risk tolerance is lower and said, look, we're going to put this ban on in the next three days. >> i mean, the rollout of this, there's certainly a lot of questions as to why the department of homeland security gave airlines 96 hours to comply instead of implementing immediately. >> yeah, i've never seen anything like this. in fact, it fits no model in wh...